AU2010277490B2 - Method of producing a polypeptide or virus of interest in a continuous cell culture - Google Patents

Method of producing a polypeptide or virus of interest in a continuous cell culture Download PDF

Info

Publication number
AU2010277490B2
AU2010277490B2 AU2010277490A AU2010277490A AU2010277490B2 AU 2010277490 B2 AU2010277490 B2 AU 2010277490B2 AU 2010277490 A AU2010277490 A AU 2010277490A AU 2010277490 A AU2010277490 A AU 2010277490A AU 2010277490 B2 AU2010277490 B2 AU 2010277490B2
Authority
AU
Australia
Prior art keywords
cell
cells
culture
less
culture system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010277490A
Other languages
English (en)
Other versions
AU2010277490A1 (en
Inventor
Daniel Fleischanderl
Leopold Grillberger
Manfred Reiter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2010277490A1 publication Critical patent/AU2010277490A1/en
Application granted granted Critical
Publication of AU2010277490B2 publication Critical patent/AU2010277490B2/en
Assigned to Baxalta GmbH, BAXALTA INCORPORATED reassignment Baxalta GmbH Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00Tissue, human, animal or plant cell, or virus culture apparatus
    • C12M3/006Cell injection or fusion devices
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0056Xeno-free medium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/98Xeno-free medium and culture conditions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/00051Methods of production or purification of viral material
    • C12N2710/00052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24087ADAMTS13 endopeptidase (3.4.24.87)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2010277490A 2009-07-31 2010-08-02 Method of producing a polypeptide or virus of interest in a continuous cell culture Active AU2010277490B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23031309P 2009-07-31 2009-07-31
US61/230,313 2009-07-31
PCT/EP2010/061191 WO2011012725A1 (en) 2009-07-31 2010-08-02 Method of producing a polypeptide or virus of interest in a continuous cell culture

Publications (2)

Publication Number Publication Date
AU2010277490A1 AU2010277490A1 (en) 2012-02-09
AU2010277490B2 true AU2010277490B2 (en) 2014-08-28

Family

ID=42668436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010277490A Active AU2010277490B2 (en) 2009-07-31 2010-08-02 Method of producing a polypeptide or virus of interest in a continuous cell culture

Country Status (22)

Country Link
US (4) US8580554B2 (enExample)
EP (2) EP2459697B1 (enExample)
JP (2) JP5808742B2 (enExample)
KR (2) KR101885046B1 (enExample)
CN (1) CN102549142B (enExample)
AU (1) AU2010277490B2 (enExample)
BR (1) BR112012002137B8 (enExample)
CA (1) CA2769354A1 (enExample)
CO (1) CO6491119A2 (enExample)
DK (1) DK2459697T3 (enExample)
EA (1) EA022219B1 (enExample)
ES (1) ES2705206T3 (enExample)
HR (1) HRP20182165T1 (enExample)
IN (1) IN2012DN00899A (enExample)
MX (2) MX2012001274A (enExample)
NZ (1) NZ597742A (enExample)
PL (1) PL2459697T3 (enExample)
PT (1) PT2459697T (enExample)
SG (1) SG178176A1 (enExample)
SI (1) SI2459697T1 (enExample)
TR (1) TR201900213T4 (enExample)
WO (1) WO2011012725A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3037386T3 (en) 2010-07-08 2025-10-01 Takeda Pharmaceuticals Co Method of producing recombinant high molecular weight vwf in cell culture
ES2890412T3 (es) * 2011-01-17 2022-01-19 Hoffmann La Roche Aparato de separación
KR101980164B1 (ko) 2011-05-13 2019-05-20 옥타파마 아게 재조합 fviii의 생산에서 진핵 세포의 생산성을 증가시키는 방법
HUE033279T2 (en) 2011-07-01 2017-11-28 Amgen Inc Mammalian cell culture
CN203129697U (zh) 2013-02-05 2013-08-14 客贝利(厦门)休闲用品有限公司 一种帐篷架杆
ES2663815T3 (es) 2011-11-24 2018-04-17 Genethon Sistema de producción de un vector lentiviral escalable compatible con aplicaciones farmacéuticas industriales
US9574167B2 (en) 2013-02-15 2017-02-21 Pharyx, Inc. Methods and apparatus for independent control of product and reactant concentrations
HK1219964A1 (zh) 2013-03-08 2017-04-21 Genzyme Corporation 治疗性蛋白药物物质的整合连续制造
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014146933A1 (en) * 2013-03-19 2014-09-25 Cmc Biologics A/S A method for producing a product (e.g. polypeptide) in a continuous cell culture fermentation process.
US10392603B2 (en) * 2013-08-30 2019-08-27 The Chemo-Sero-Therapeutic Research Institute Method of viral purification
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
AU2015240354A1 (en) 2014-04-01 2016-11-17 Advantech Bioscience Farmaceutica Ltda. Stabilization of Factor VIII without calcium as an excipient
MX2016012870A (es) 2014-04-01 2017-05-12 Advantech Bioscience Farmacêutica Ltda Formulaciones de factor viii estables con bajo tenor de azucar - glicina.
EP3158055B1 (en) * 2014-06-13 2019-09-11 CSL Limited Improved production of recombinant von willebrand factor in a bioreactor
KR20240173213A (ko) 2016-01-26 2024-12-10 베링거 인겔하임 인터내셔날 게엠베하 연결된 관류 대 연속-유동식 교반-탱크 반응기 세포 배양 시스템
SG11201809051YA (en) * 2016-04-15 2018-11-29 Boehringer Ingelheim Int Cell retention device and method
JP7408389B2 (ja) * 2016-12-21 2024-01-05 エフ. ホフマン-ラ ロシュ アーゲー 真核細胞の増殖制御方法
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
WO2019239780A1 (ja) * 2018-06-15 2019-12-19 富士フイルム株式会社 細胞培養方法、細胞培養装置、及び生産物の製造方法
AU2019332764B2 (en) 2018-08-31 2025-05-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
CN113355297A (zh) * 2021-06-23 2021-09-07 吉林冠界生物技术有限公司 一种灌流式培养全悬浮mdck细胞生产重组禽流感病毒的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019512A (en) 1989-03-17 1991-05-28 Baxter International Inc. Spin filter for removing substantially cell-free culture medium from suspension cell culture system
US5626734A (en) 1995-08-18 1997-05-06 University Technologies International, Inc. Filter for perfusion cultures of animal cells and the like
AU2001291653A1 (en) 2000-10-02 2002-04-15 Novo-Nordisk A/S Industrial-scale serum-free production of recombinant factor vii in mammalian cells
IL161858A0 (en) * 2001-11-28 2005-11-20 Sandoz Ag Cell culture process
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
AU2006257073B2 (en) 2005-06-17 2011-08-04 Children's Medical Center Corporation ADAMTS13-comprising compositions having thrombolytic activity
ES2474573T3 (es) * 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
PL2235197T3 (pl) * 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBINSON, D.K. et al. Journal of Biotechnology, 1992, Vol.22, pages 41-50. *

Also Published As

Publication number Publication date
HRP20182165T1 (hr) 2019-03-08
TR201900213T4 (tr) 2019-02-21
SG178176A1 (en) 2012-03-29
JP2013500710A (ja) 2013-01-10
NZ597742A (en) 2014-02-28
US20140038264A1 (en) 2014-02-06
US10221400B2 (en) 2019-03-05
AU2010277490A1 (en) 2012-02-09
EP2459697A1 (en) 2012-06-06
KR101885046B1 (ko) 2018-08-02
US10745672B2 (en) 2020-08-18
US8580554B2 (en) 2013-11-12
JP2015062436A (ja) 2015-04-09
CO6491119A2 (es) 2012-07-31
MX353610B (es) 2018-01-18
WO2011012725A1 (en) 2011-02-03
US9650612B2 (en) 2017-05-16
SI2459697T1 (sl) 2019-03-29
IN2012DN00899A (enExample) 2015-04-03
BR112012002137B8 (pt) 2020-05-12
BR112012002137A2 (pt) 2015-09-15
MX2012001274A (es) 2012-06-01
JP6177260B2 (ja) 2017-08-09
PT2459697T (pt) 2019-01-21
US20190153400A1 (en) 2019-05-23
ES2705206T3 (es) 2019-03-22
JP5808742B2 (ja) 2015-11-10
EA201270213A1 (ru) 2012-06-29
KR20170077286A (ko) 2017-07-05
CN102549142B (zh) 2014-07-16
EP2459697B1 (en) 2018-10-17
EP3480292A1 (en) 2019-05-08
WO2011012725A8 (en) 2011-05-05
PL2459697T3 (pl) 2019-04-30
US20110086411A1 (en) 2011-04-14
DK2459697T3 (en) 2019-01-28
EA022219B1 (ru) 2015-11-30
US20180051261A1 (en) 2018-02-22
CA2769354A1 (en) 2011-02-03
BR112012002137B1 (pt) 2020-04-14
CN102549142A (zh) 2012-07-04
KR20120038531A (ko) 2012-04-23
KR101752789B1 (ko) 2017-06-30

Similar Documents

Publication Publication Date Title
AU2010277490B2 (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
PT2634242T (pt) Processo melhorado para cultura de células
JP5096920B2 (ja) ウイルス物質の製造方法
Narumi et al. Recovery of human mesenchymal stem cells grown on novel microcarrier coated with thermoresponsive polymer
HK40008436A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
HK1169439A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
HK1169439B (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
AU2009272857B2 (en) Scalable process for culturing PER.C6 cells and producing products therefrom
JPH05207874A (ja) 無血清培地
JP2011004754A (ja) 組換え安定細胞クローン、その産生およびその使用
JP2010099093A (ja) 組換え安定細胞クローン、その産生およびその使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BAXALTA GMBH; BAXALTA INCORPORATED

Free format text: FORMER OWNER WAS: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.

PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXALTA GMBH; BAXALTA INCORPORATED